ABBV-969 is a dual-target antibody-drug conjugate targeting PSMA and STEAP1, data about its radiographic progression-free survival data have just been released, confirming a median rPFS of approximately 15 months in heavily pretreated metastatic castration-resistant prostate cancer. The study demonstrates a signal far exceeding the 4- to 5-month rPFS historically seen with cabazitaxel in the same […]
YL201, a B7-H3–targeting antibody–drug conjugate, is showing notable activity in advanced metastatic castration-resistant prostate cancer (mCRPC), including patients who have progressed after androgen receptor–targeted therapy and chemotherapy. In a phase 2 study of 82 heavily pretreated patients, the drug delivered a confirmed PSA50 response rate of 38.5%, an objective response rate of 29.5%, and a […]
ABBV-969, a first-in-class dual-targeting antibody-drug conjugate (ADC), is emerging as a promising new therapeutic candidate for patients with metastatic castration-resistant prostate cancer (mCRPC), particularly in the late-line setting where treatment options are limited and outcomes remain poor. Designed to simultaneously target prostate-specific membrane antigen (PSMA) and six-transmembrane epithelial antigen of prostate 1 (STEAP1), both highly […]
HS-20093 has received Breakthrough Therapy designation from China’s National Medical Products Administration for metastatic castration-resistant prostate cancer. The designation covers patients previously treated with novel endocrine therapy and taxane-based chemotherapy, a setting where later-line treatment options remain limited. HS-20093 is a B7-H3-targeted antibody-drug conjugate designed to bind tumor cells expressing B7-H3 and deliver a cytotoxic […]
A promising new bispecific antibody-drug conjugate (ADC) known as IDE034 is entering early clinical testing in patients with advanced solid tumors, including prostate cancer, marking a potential step forward in precision oncology. This Phase 1a/1b trial, which began dosing its first patient in February 2026, targets tumors expressing both B7-H3 and PTK7, two surface proteins […]
SHR-A1921, also known as tizetatug rezetecan, represents a significant advancement in targeted cancer therapeutics, specifically designed to exploit TROP2 overexpression in aggressive malignancies including prostate cancer. This novel antibody-drug conjugate (ADC) has demonstrated compelling preclinical activity in prostate cancer models and encouraging early clinical results across multiple solid tumors, positioning it as a potential therapeutic […]
BNT324 (DB-1311) is rapidly emerging as one of the most promising new agents in metastatic castration-resistant prostate cancer (mCRPC), with a data package that is unusually strong for a first-in-class B7-H3–targeting antibody–drug conjugate and now compelling enough to justify a head‑to‑head Phase 3 trial against docetaxel. The reason it has attracted so much attention is […]
GSK5764227 represents a promising advancement in treating metastatic castration-resistant prostate cancer (mCRPC). This antibody-drug conjugate targets B7-H3, a protein overexpressed on prostate cancer cells, delivering a topoisomerase I inhibitor payload directly to tumors while minimizing damage to healthy tissues. Early data from broader solid tumor studies show the drug’s monotherapy potential, with objective response rates […]
MHB048C is an investigational antibody–drug conjugate designed to target prostate‑specific membrane antigen (PSMA) on tumor cells and selectively deliver a DNA topoisomerase I–inhibiting cytotoxic payload. By combining a PSMA‑directed antibody with a potent payload, the drug aims to exploit the high and relatively restricted expression of this surface antigen in advanced prostate cancer and in […]
TD001, is an investigational antibody-drug conjugate directed against prostate-specific membrane antigen (PSMA), developed for the treatment of men with metastatic castration-resistant prostate cancer whose tumors express PSMA will start recruiting patients for its phase 1/2 clinical trial. Mechanistically, TD001 combines a monoclonal antibody directed against PSMA with a topoisomerase I inhibitor payload, exatecan, linked through […]
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsHide notification onlySettingsWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.
If you do not want that we track your visit to our site you can disable tracking in your browser here:
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
The following cookies are also needed - You can choose if you want to allow them:
You can read about our cookies and privacy settings in detail on our Privacy Policy Page.
Privacy Policy